Responses
Regular and Young Investigator Award Abstracts
Clinical Trial In Progress
721 Ongoing phase 1 study of MP0317, a FAP-CD40 DARPin, shows a favorable safety profile and early evidence of tumor-localized CD40 activation in patients with advanced solid tumors
Compose a Response to This Article
Other responses
No responses have been published for this article.
